Agios Pharmaceuticals(AGIO) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, PYRUKYND generated $20 million in net revenue, an 86% increase year-over-year and a 55% sequential increase from $13 million in Q3 2025 [7][10] - Full-year 2025 revenue for PYRUKND reached $54 million, reflecting robust year-on-year growth [7][10] - The company ended 2025 with approximately $1.2 billion in cash, providing flexibility for future investments [8][11] Business Line Data and Key Metrics Changes - U.S. revenue for PYRUKND in Q4 was $16 million, driven by commercial focus in PK deficiency and favorable growth adjustments [10] - Ex-U.S. revenue was $4 million in Q4, primarily due to inventory stocking ahead of demand [11] - Cost of sales for Q4 was $1.9 million, while R&D expenses were $88.1 million, reflecting an increase associated with advancing the pipeline [11] Market Data and Key Metrics Changes - The U.S. launch of ACTIVASE for thalassemia is underway, with expectations for U.S. PK deficiency revenues in 2026 to be between $45-$50 million [10] - The company anticipates a sequential decline in ex-U.S. revenues into Q1 2026 [11] Company Strategy and Development Direction - The company outlined its 2026 strategic priorities, focusing on executing the launch of Pyrukynd, expanding the PK activation franchise, advancing early-stage pipeline programs, and maintaining financial discipline [5][6] - The company aims to leverage its existing commercial presence in thalassemia and PK deficiency to achieve profitability [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the early market response to ACTIVASE, noting strong engagement from physicians and patients [16] - The company is preparing for a pre-sNDA meeting with the FDA regarding mitapivat for sickle cell disease, which is a critical step in defining the regulatory path [25][44] Other Important Information - The company has completed enrollment in the phase II sickle cell disease trial of tebapivat, with top-line results expected in the second half of 2026 [8][20] - The company is committed to financial discipline, anticipating operating expenses in 2026 to be roughly flat compared to 2025 [12] Q&A Session Summary Question: On the ACTIVASE launch and prescription updates - Management noted that early demand for ACTIVASE is encouraging, with 44 prescriptions written by REMS-certified physicians in the first five weeks of launch [31] - It is expected that prescriptions will grow ahead of revenues due to a 10-12 week conversion time from prescription to treatment initiation [31][32] Question: On sickle cell and tebapivat expectations - Management indicated that the phase II tebapivat trial is a dose-finding trial, and they are excited about the potential hemoglobin response based on previous data [35][36] Question: On payer dynamics and SG&A changes - The payer mix for thalassemia is similar to PK deficiency, with most patients under commercial payers, and initial market access is expected to occur through medical exceptions [93] - SG&A expenses will need to scale up for sickle cell, but the existing infrastructure from PK deficiency and thalassemia will be leveraged [95]